RVPH - Reviva Pharmaceuticals Holdings, Inc. EV/EBITDA Multiple
The share price retrospective for Reviva Pharmaceuticals (RVPH) on the GURU.Markets platform demonstrates an EV/EBITDA of 0.00. The company is currently preparing to launch an innovative neuroleptic as it finalizes key tests. The business relies on the development of Brilaroxazine, which treats psychosis without weight-gain side effects. This sector is considered a safe haven, as the demand for psychiatric care is independent of market cycles, while success depends on FDA verdicts.
Comprehensive metric breakdowns and analytics for revivapharma.com (RVPH)
- stock price and consensus target price:
- market capitalization statistics:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Reviva Pharmaceuticals|RVPH - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Reviva Pharmaceuticals Holdings, Inc.|RVPH - Company Aggregate Indebtedness|Debts to Book Capitalization Reviva Pharmaceuticals, Inc.|RVPH - Company Long-Term Loans and Borrowings|Company Short-Term Debts Reviva Pharmaceuticals|Quick Liquidity revivapharma.com
- net income and valuation multiples indicators:
RVPH - Final Profit|Expected Profit Reviva Pharmaceuticals|RVPH - Price to Earnings Ratio|Forward P/E Multiple Reviva Pharmaceuticals|RVPH - PEG Multiple|EV/EBITDA Multiple Reviva Pharmaceuticals, Inc.|RVPH - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Reviva Pharmaceuticals|RVPH - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months revivapharma.com|RVPH - Earnings growth in current year|Expected earnings per share growth for next year Reviva Pharmaceuticals
- sales revenue and business income indicators:
Fundamental valuation:Reviva Pharmaceuticals Holdings RVPH
To build a defensive portfolio, fundamental screening requires an analysis of EV/EBITDA, which compares the total enterprise value (market capitalization and net debt) with operating profit before depreciation and amortization. In the case of Reviva Pharmaceuticals (RVPH), which is seeking a strategic partner for drug commercialization, the company's trend EV/EBITDA level reflects the value of its assets relative to their current efficiency during the completion of clinical trials.
Key competitors
Biogen Corp - Enterprise Value to EBITDA Ratio|Neurocrine Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Regencell Bioscience - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio axsome.com AXSM|ACAD (ACADIA Pharmaceuticals Inc.) - Enterprise Value to EBITDA Ratio|XENE (Xenon Pharmaceuticals Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VKTX (Viking Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Supernus Corp|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|DNLI (denalitherapeutics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN (Biohaven Ltd) - Company Value to Operating Income Before Depreciation Ratio|Amylyx - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation TRVI (Trevi Corp)|PRAX: EV/EBITDA Multiple|anavex.com (AVXL) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell|PRTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|Enterprise Value to EBITDA Ratio Annexon Biosciences Inc. ANNX|EV/EBITDA Multiple OMER (Omeros)|EV/EBITDA Multiple neurogene.com NGNE|AC Immune SA - EV/EBITDA Multiple|Voyager Therapeutics Inc (VYGR) - Enterprise Value to EBITDA Ratio|NMRA: EV/EBITDA Multiple|Company Value to EBITDA Scilex Holding Company, Inc. (SCLX)|Enterprise Value to EBITDA Ratio TVGN|EV/EBITDA Multiple Alpha Cognition Corp|Enterprise Value to EBITDA Ratio CGTX (Cognition Therapeutics, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio IKT|EV/EBITDA Multiple SAVA (Cassava)|Total Company Value to Operating Income Before Depreciation Ratio Assertio Holdings (ASRT)|Coya - EV/EBITDA Multiple|Vistagen Therapeutics (VTGN) - Enterprise Value to EBITDA Ratio|OVID: EV/EBITDA Multiple|Acumen Pharmaceuticals Inc. (ABOS) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ATHE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|Total Company Value to Operating Income Before Depreciation Ratio pepgen.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|Business Value to Operating Income Before Depreciation RLMD|ANVS: Enterprise Value to EBITDA Ratio|GRCE: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio KLTO (Klotho Neurosciences)|NRSN (NeuroSense Therapeutics Ltd) - EV/EBITDA Multiple|MTVA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|heliusmedical.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Company Value to EBITDA|NERV: Enterprise Value to EBITDA Ratio|ATHA - EV/EBITDA Multiple|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Alzamend Neuro - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Company Value to EBITDA Protagenic PTIX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATXI (Avenue Therapeutics, Inc)|BrainStorm Cell Therapeutics Inc. (BCLI) - Company Value to EBITDA|CARA: Enterprise Value to EBITDA Ratio|CHRO: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ELYM: EV/EBITDA Multiple|ITCI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio LBPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MRNS|EV/EBITDA Multiple NKGN|EV/EBITDA Multiple neurobopharma.com (NRBO)|Sage Therapeutics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VIGL|WENA: EV/EBITDA Multiple|cerevel.com - Business Value to Operating Income Before Depreciation
